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Abstract: Interferon alpha (IFN-α) has been used as a maintenance therapy after autologous stem cell transplantation (ASCT) for 
  multiple myeloma (MM) patients. In this study, we combined GM-CSF with IFN-α in order to improve IFN tolerance in post-ASCT 
myeloma patients. Primary aims were to evaluate myelotoxicity and effectiveness of this maintenance therapy. The treatment included 
4 × 106 units of IFN-α and 125 µg/m2 of GM-CSF given three times a week for twelve months. Twenty seven patients were enrolled 
within 120 days after ASCT. One patient discontinued treatment due to thrombocytopenia and seven others were taken off study due to 
flu-like symptoms and/or increase in liver enzymes. With a median follow-up of 45.5 months, the median overall survival was not 
reached while the median progression-free survival was 28 months. Eleven patients (42%) have remained in very good partial remission 
or complete remission since ASCT. In conclusion, our results demonstrate that maintenance with GM-CSF and IFN-α is safe and 
effective.
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Introduction
The standard treatment of newly diagnosed multiple 
myeloma  (MM)  consists  of  induction  therapy  fol-
lowed by single or tandem autologous stem cell trans-
plant  (ASCT).1–4  However,  although  survival  is 
improved, the majority of these patients still relapse 
despite achieving good initial responses and very few 
are  cured  from  MM.  Post  ASCT  interventions 
have  been  sought  to  delay  relapses  and  possibly 
increase the number of cured patients. Post ASCT 
maintenance regimens have been studied with usu-
ally  some  benefits.  Until  recently,  interferon-α 
(IFN-α) with or without steroids was the main main-
tenance regimen.5,6
Since the first report by Mandelli et al7 on the useful-
ness of IFN-α as a maintenance drug for MM patients, 
multiple  studies,  including  randomized  and  meta-
analysis studies, have demonstrated conflicting results 
in regards to the effects of IFN-α maintenance, after 
conventional or high-dose chemotherapy, on progres-
sion-free survival (PFS) and/or overall survival (OS).8–
14 These results, the toxicity profile, and the availability 
of  new  effective  novel  agents  have  resulted  in  the 
decline in using IFN-α for maintenance in MM patients. 
On the other hand, long-term therapy with interferon in 
other diseases, such as CML and hairy cell leukemia,15,16 
has been well tolerated and resulted in long-term dis-
ease-free survival. A hint of long-term effect has been 
noted in data published by the Italian Multiple Myeloma 
Study Group on 10 year follow up observations of 9 
patients still alive in the interferon-maintained group 
versus 2 in the unmaintained group.17
Although  IFN-α  maintenance  post  autologous 
transplant has been shown to be beneficial, not all 
MM patients can start this treatment due to delayed 
recovery of blood counts and many more will stop 
therapy  due  to  significant  myelosuppression.  Our 
unpublished data on 33 MM patients who underwent 
ASCT revealed that 5 of these patients were unable 
to start IFN-α due to slow hematopoietic recovery 
(historical control), while 7 more had to discontinue 
IFN-α due to significant drop in blood counts with 
grade $IV toxicity. Thus, a significant proportion of 
patients are not able to benefit from IFN-α due to 
low  blood  counts  after  ASCT  or  IFN-α-induced 
myelosuppression. These results are consistent with 
findings reported in other published studies.13,18,19
GM-CSF has been shown to shorten duration of 
chemotherapy-induced myelosuppression therapy.20–24 
Furthermore,  GM-CSF  activates  macrophages, 
increases functional capacity of monocytes, mediates 
proliferation, maturation and migration of dendritic 
cells, and increases the production of angiostatin by 
macrophages that inhibit angiogenesis.25–27 Because 
of these multiple functions, some studies have sug-
gested  possible  GM-CSF  anti-tumor  activity  in 
patients with melanoma and advanced prostate   cancer 
as  well  as  other  tumors.28–31 The  use  of  GM-CSF/
IFN-α combination has been reported in patients with 
CML in chronic phase and melanoma.32–34 The addi-
tion of GM-CSF allowed the escalation of IFN-α dose 
in half the patients with CML and showed improve-
ment in overall response rate and the complete cyto-
genetic responses. No toxicity was attributed to the 
addition of GM-CSF.32
In this study, our aim was to determine whether the 
addition of GM-CSF to IFN-α would allow the use of 
IFN-α  maintenance  in  higher  proportion  of  MM 
patients  and  thus  possibly  improve  its  direct  anti- 
myeloma effect and prolong survival.
patients and Methods
Patients
This trial was a prospective phase II study evaluating 
the  myelotoxicity  and  effectiveness  of  combined 
maintenance  with  GM-CSF  and  IFN-α  in  post- 
transplant MM patients. The study was approved by 
the institutional review board. Between January 2003 
and June 2007, 27 patients were enrolled after sign-
ing informed consent. Eligibility for enrollment to 
the study included .15 year of age, no more than 
120  days  from  last  ASCT,  ECOG  performance 
  status #2.0, transfusion independence, platelet count 
above  75,000/mm3,  absolute  granulocyte  count 
(AGC) of $1500/mm3, satisfactory vital organ func-
tion, and no serious active infections. Patients with 
slow count recovery were allowed to start with single 
agent  GM-CSF  in  order  to  improve  their  count 
recovery  and  thus  meet  the  above  requirements. 
Patients with progressive disease were excluded from 
study.
Clinical data were collected on the stage of dis-
ease, time from diagnosis to transplant, the number   
of  prior  treatments  including  radiation  therapy, GM-CSF and IFN-α maintenance for myeloma patients
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β2-microglobulin (β2M) and results of cytogenetics/
FISH analysis.   Disease status was evaluated before 
transplant, at the time of study treatment (IFN-α + 
GM-CSF) and at the completion of study treatment 
and response was   classified according to the Interna-
tional  Myeloma  Working  Group  uniform  response 
criteria.35 At the time of treatment, toxicity was evalu-
ated as an effect of combined GM-CSF with IFN-α, 
and classified according to the NCI Common Toxic-
ity Criteria (CTC version 3).
Treatment plan
All patients underwent ASCT according to standard 
practice  at  our  institution  as  published  before.36 
Within 120 days of completion of ASCT/induction 
treatment, all eligible patients were started on IFN-α 
and GM-CSF simultaneously Monday, Wednesday, 
and Friday each week. IFN-α was given subcutane-
ously  with  an  initial  dose  of  1  ×  106  units  with 
weekly increase up to maximal dose of 4 × 106 if 
tolerated.  GM-CSF  was  given  subcutaneously  at 
125 µg/m2 on the same days as the IFN-α. GM-CSF 
was provided to patients free of charge for maxi-
mum of one year by the sponsor (Immunex/Berlex). 
After one year, patients could continue on IFN-α 
with/without GM-CSF off study at the discretion of 
the  treating  physician.  If  at  any  time  while  on 
GM-CSF, the WBC exceeded 20,000/mm3, then the 
GM-CSF dose would be decreased by 50%. If at the 
time of enrollment AGC was ,1500/mm3, the patient 
would start GM-CSF daily until AGC $ 1500/mm3 
before  IFN-α  was  started.  IFN-α  treatment  was 
stopped  if  the  PLT  count  dropped  ,50,000/mm3 
and  restarted  at  a  lower  dose  when  the  PLT 
count $75,000/mm3. Study drugs were to be stopped 
for persistent constitutional symptoms such as fever/
flu like symptoms or significant abnormalities in liver 
function tests beyond the first two weeks of treatment 
or later if related to higher IFN dose. Restarting IFN 
treatment at a lower dose was allowed within two 
weeks and if the symptoms or abnormalities recurred, 
then the patient was taken off study.
Statistical analysis
In this study, myelotoxicity was assessed using the 
NCI Common Toxicity Criteria (CTC) version 3 and 
reported using descriptive statistics.
Effectiveness  of  maintenance  was  assessed  by 
PFS. In this intent to treat analysis, the PFS and OS 
were estimated by Kaplan-Meier method. PFS is the 
time  from  first  ASCT  to  either  confirmed  25% 
increase/recurrence of paraprotein, doubling the per-
centage of plasmacytosis in BM, appearance of new 
lytic  lesions  or  any  combination.  Patients  were 
  censored at the last follow up. OS is the time from 
first ASCT to death from any reason. All statistical 
analyses were performed using the GraphPad   software 
Prism 4 (San Diego, CA).
Results
Patient characteristics
Total of 27 patients signed informed consents; how-
ever one patient did not start treatment and was not 
considered for the analysis. The patient characteris-
tics are shown in Table 1 and reflect a representative 
group of MM patients.
Among the 26 study participating patients, 19 were 
white, six African American, and one Asian. At diag-
nosis, one patient had stage IA, 11 were stage IIA, one 
stage IIB, 10 IIIA and three were stage IIIB. The cyto-
genetics and FISH performed at the time of diagnosis 
showed that 18 patients had normal karyotype, two had 
complex abnormalities, 3 with deletion of chromosome 
13 and 2 of them showed both deletion of chromosome 
13 and complex abnormalities, and two more had other 
cytogenetic abnormalities. Twenty patients had β2M at 
diagnosis with a median value of 2.3 mg/L, and 6 of 
them had values greater than 4 mg/L.
The  median  number  of  pre-transplant  therapies 
was 1 (range, 1–3), and 8 of them also received prior 
radiation  therapy.  Pre-transplant  regimens  used 
included VAD (15 patients), thalidomide/dexametha-
sone (9 patients), hyper CVAD (2 patients), melphalan 
(1 patient), and lenalidomide (2 patients). At the time 
of  first  transplant,  four  patients  were  in  complete 
remission (CR), 10 in very good partial remission 
(VGPR), 11 in partial response (PR), and one had 
minimal response (MR).
The median follow up from the completion of IFN/
GM-CSF study was 33 months (range 5–66) and that 
from the first ASCT was 45.5 months (range 14–73). 
Four  patients  received  planned  tandem  transplants 
prior  to  starting  IFN  treatment.  The  conditioning 
  regimen for ASCT was busulfan, cyclophosphamide Salmasinia et al
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and etoposide in 16 patients as described before,36 
while the rest received melphalan 200 mg/m2. There 
were  5 ASCT  and  3  non-myeloablative  allogeneic 
  transplants done for relapsed disease after completion 
of the IFN/GM-CSF treatment.
IFn-α/GM-csF Treatment
Table  2  summarizes  the  statistical  analysis  of  the 
IFN-α/GM-CSF combined treatment in comparison 
to single agent IFN-α received by a historical control 
group  of  patients  treated  in  our  institution.  In  the 
study  group,  the  median  length  of  treatment  with 
IFN-α was 11.5 months (range, 1–60), while it was 
only 8 months (range 0.5–54) in the control group. 
Two patients from the study group had a slow counts 
recovery  after  ASCT  and  were  treated  with  daily 
GM-CSF for 2 weeks before adding the IFN. Other-
wise all enrolled patients were able to start treatment 
on  time  between  days  90  and  120  after  ASCT. 
Ten patients prematurely   discontinued IFN-α after a 
median time of 2.5 months (range 1–10 months), five 
of whom experienced persistent flu-like symptoms, 
one had elevated liver enzymes, one had both flu-like 
symptoms and elevated liver enzymes, two relapsed 
and one patient experienced grade 3 thrombocytope-
nia. Significant leukopenia was not seen in any of the 
study  patients.  These  patients  who  stopped  study 
drugs did not receive other treatments until disease 
progression. The expected length of treatment with 
GM-CSF and IFN-α was one year long. However, 
two patients prematurely discontinued GM-CSF due 
to skin rash and cellulitis. Nine patients continued on 
with IFN-α alone after completion of one year com-
bined therapy, four of whom were still on IFN-α as of 
this analysis.
Table 2. IFn-α treatment statistics in study (IFn/gM-CSF) 
versus historical control (IFn only) groups.
patient groups study  
group
control†
IFn dose, IU (106) 3 (2–4)* 3 (1–4)
Length of IFn therapy, mo 11.5 (1–60) 8 (0.5–54)
Prematurely discontinued IFn 10 14
  reasons for discontinuation
    Flu like symptoms 5 3
    elevated liver enzymes 1 1
    Both of the above 1 0
    relapse 2 3
    Thrombocytopenia only 1 0
    Pancytopenia/Leukopenia 0 7**
Prematurely discontinued 
gM-CSF
2 nA
  reason for discontinuation
    Skin rash/cellulitis 2 nA
Using IFn . 1 year 9 6
Currently on IFn  4 nA
notes: *Results reflect median and (range), otherwise number of patients 
in  each  category;  †33  patients  were  included  in  the  historical  control 
group, only 25 received IFn-α therapy while 8 of them were not able to 
start the IFn treatment due to delayed count recovery (4), thrombocytopenia 
(1), early relapse (2), and unknown reason (1); **Significantly different 
with two tailed P = 0.0173.
Table 1. Patient characteristics.
characteristics study group
number of patients  26
Age, years  59 (30–71)*
Sex, M/F 14/12
race, W/AA/other 19/6/1
MM stage
  I A 1
  II A 11
  II B 1
  III A 10
  III B 3
Disease status prior to ASCT
  Cr 4
  VgPr 10
  Pr 11
  Mr 1
ASCT
  CD34+ cell dose/kg 5.1 × 106 (2.5–10)
  Tandem ASCT 4
Chromosome/FISh**
  normal 18
  Complex 1
  Del 13 1
  Complex/del 13 2
  Other 2
β2M 2.3 (0.6–9.2)
Time from diagnosis to ASCT, mo 6 (3–25)
Follow up from last ASCT, mo 45.5 (14–73)
number of prior therapy 1 (1–3)
  Patients with $2 regimens 6
Prior radiation therapy 8
number of salvage transplants
  Autologous 5
  Allogeneic 2
notes: *Data reflects median, (range), otherwise number of patients in 
each category; **not all patients had chromosomal studies at diagnosis.
Abbreviations: AA, African American; W, white; mo, months; M, male;   
F, female.GM-CSF and IFN-α maintenance for myeloma patients
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Patients in the historical control group   underwent 
single ASCT  between  November  1996  and  March 
2000. However, only 25 of those patients were able 
to start the IFN-α while 8 were not able to start the 
  treatment. The reasons for not being able to start 
included delayed counts recovery (4), thrombocy-
topenia only (1), early relapse (2), and one unknown 
reason.  The  median  length  of  IFN  therapy  was 
8 months (range, 0.5–54). Fourteen patients prema-
turely discontinued the treatment after median of 
3 months (range 0.5–8 months). The reasons for dis-
continuation included relapse (3), pancytopenia (5), 
leukopenia (2), flu like symptoms (3), and elevated 
liver  enzymes  (1).  Despite  obvious  differences 
between the two groups in terms of the ability to 
start therapy with IFN and the number of patients 
who had to stop IFN, the proportion of patients who 
discontinued IFN therapy in each group was not sig-
nificantly different using the logrank test (10 patients 
in the study group vs. 14 patients in the control group, 
P = 0.325). In addition, the median length of IFN-α 
treatment was not significantly different between the 
two groups (11.5 months in the study group versus 
8 months in the control, P = 0.341). On the other 
hand,  the  frequency  of  myelotoxicity  in  the  study 
group (1 patient with thrombocytopenia) was signifi-
cantly less than that seen in the control (7 patients) 
group (two tailed P = 0.0173).
Treatment-related toxicity
The  treatment  related  toxicity  of  GM-CSF/IFN-α 
combined therapy is given in Table 3 and was classi-
fied according to the NCI CTC (Version 3). Three 
patients developed persistently elevated liver enzymes 
that resulted in discontinuation of therapy in 2 of them. 
Six  patients  experienced  skin  rash/cellulitis  mostly 
related to GM-CSF, 4 of whom had only grade I toxic-
ity while 2 had grade IV. Eight patients developed flu-
like symptoms, 3 patients with grade II and 5 patients 
with  grade  IV.  Two  patients  had  grade  II  and  III 
  thrombocytopenia, 2 patients had grade I fatigue, and 
another  2  had  grade  II  leukocytosis.  None  of  the 
patients  experienced  pancytopenia  or    leukopenia. 
There was no grade V toxicity resulting in death or 
hospitalization.
Outcomes and survival analysis
All  patients  survived  more  than  one  year  post- 
transplant and the disease status was evaluated prior 
to  and  at  completion  of  12-month  therapy  (see 
Table  4).  Prior  to  treatment  initiation,  9  patients 
were determined to be in PR, 5 in CR, and 12 in 
VGPR.  At  the  completion  of  12-month  therapy, 
the  number  of  patients  with  PR  decreased  to  3, 
CR  increased  to  8,  9  were  still  in  VGPR  while 
6 patients relapsed. Three of the relapsed patients 
were those with chromosome 13/13q deletion and 
two of them died from progressive disease. Overall, 
eleven patients (42%) have remained in VGPR/CR 
since ASCT.
At a median follow up of 45.5 months (range, 
14–73) from the first ASCT, 20 patients are still alive, 
8  of  whom  are  relapse-free  for  a  minimum  of 
14  months,  and  6  have  died.  Figure  1  shows  the 
Kaplan-Meier estimates of OS and PFS. The 2-year 
OS probability (±SD) was 0.8 ± 0.08 and the PFS 
was  0.59  ±  0.1.  Median  OS  was  not  reached  for 
the  study  treatment  group,  while  the  median  PFS 
was 28 mo.
A  sub-analysis  of  the  effects  of  IFN-α  and 
GM-CSF  combination  in  high-risk  patients  with  Table 3. Treatment-related (IFn+gM-CSF) toxicity using 
CTC version 3.
symptoms* 0 I II III IV
Liver abnormalities 1 1 1
Skin rash (cellulitis) 4 2
Flu-like symptoms 3 5
Thrombocytopenia 1 1
Fatigue 2
Leukocytosis 2
note: *Some patients had more than one side effect due 
to treatment.
Table  4.  Disease  status  at  the  time  of  initiation  and 
  completion of 12-month therapy with IFn-α + gM-CSF.
status prior At completion
Pr 9* 3
Cr 5 8
VgPr 12 9
relapse n/A 6
note: *Results reflect number of patients in each response category.Salmasinia et al
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β2M . 4 mg/L, chromosome 13/13q deletion and/or 
complex abnormalities was performed (Table 5). The 
results  indicate  that  the  combination  maintenance 
resulted in long-term PFS and OS in 50% of patients 
with elevated β2M, however the median PFS for this 
high-risk group was much shorter (13 mo) than that 
for the whole study group (28 mo).
Discussion
In this study, we report the use of GM-CSF/IFN-α 
combination therapy as a maintenance treatment 
for multiple myeloma patients following single or 
  tandem ASCT. Despite the relatively small number 
of patients enrolled, our results show that the addi-
tion  of  GM-CSF  to  IFN-α  helps  ameliorate  the 
myelotoxicity of the latter. IFN related myelotoxicity 
is especially frequent and an important impediment 
to its use in patients after ASCT as reported by others 
and it can be seen in high numbers of patients.13,18,19 
Our results show that the addition of GM-CSF may 
allow the use of IFN maintenance in more patients 
and  it  can  significantly  reduce  the  prevalence  of 
cytopenias  in  comparison  to  our  own  historical 
experience.
The use of the combination was associated with 
28 month PFS and the OS was not reached at the time 
of  analysis. These  results  compare  positively  with 
published studies reporting the use of IFN-α mainte-
nance after ASCT.14,38,39
Despite overcoming the problem of IFN-α induced 
myelosuppression with GM-CSF, significant number 
of patients still could not tolerate IFN-α due to other 
constitutional  symptoms.  Ways  to  overcome  such 
effects  have  been  explored  by  using  peginterferon 
with some improvement in quality of life.40 However, 
it seems that some patients tolerate IFN without any 
side effects, while others will have symptoms even 
with the lowest dose possible. The mechanism for 
causing these side effects is not known, but the indi-
vidual variability implies different pharmacodynamic 
responses between patients as described with other 
interferons41,42 Future pharmacogenomics research in 
these patients may be key to improving and individu-
alizing  the  use  of  IFN-α  in  the  treatment  of  MM 
patients.
The main aim of maintenance therapy after ASCT 
in MM patients is to improve PFS and possibly OS. 
Achieving  such  positive  effects  depends  on  some 
known  primary  prognostic  factors.  Although  our 
study showed significant improvement in PFS over 
our historical control (not published), our sub analysis 
results also show that some high-risk patients, especially 
with  β2M  .  4  mg/L  but  not  with  chromosome 
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Figure 1. The Kaplan-Meier estimates of survival status of MM patients 
in the study group. Median OS was not reached while the median PFS 
was 28 mo.
Table 5. effect of IFn-α/GM-CSF maintenance in high risk myeloma patients, as defined by the presence of β2M . 4 mg/L 
and/or del 13/13q and/or complex chromosomal abnormalities at diagnosis.
subject β2M; Repeat Disease stage pFs (mo) Os (mo) cytogenetic/FIsH status
1 9.2; 9.8 IIIB 12 32 normal Dead
2 4.3; 2.9 IIIA 9 12 normal Dead
3 7.7; 6.4 IIIB 40 58 normal Alive
4 5.8; 2.7 IIIB 11 25 Complex (49, -X and 13q del) Dead
5 8.8; 2.5 IIA 58 58 normal Alive
6 9.6; 4.6 IIB 39 39 normal Alive
7 2.2; 2.4 IIA 14 20 13 del/Complex Dead
8 2.0; 2.6 IA 12 28 13q del Alive
Abbreviations: del, deletion; complex, multiple chromosomal abnormalities (.3).GM-CSF and IFN-α maintenance for myeloma patients
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13  deletions,  may  benefit  from  IFN-α/GM-CSF 
  maintenance. Our study argues for the continued con-
sideration of IFN-α especially in view of the fact that 
the current alternative, thalidomide, has significant 
toxicity and uncertainties.43,44 Furthermore, published 
studies have all reported problems with tolerability 
and discontinuation of therapy with lenalidomide,45,46 
thalidomide43,44,47–49 or bortezomib50–53 due to various 
severe  toxicities  including  myelosupprssion  and 
infection, neuropathy, deep venous thrombosis and 
pulmonary emboli. Thus, we suggest that IFN-α is 
not different than any of these new novel drugs and 
that  expanded  combination  maintenance  therapy, 
including  GM-CSF  and  IFN-α,  should  be  further 
investigated.  Few  studies  have  been  published  on 
combining  interferon  or  peginterferon  with 
thalidomide,54–56 which showed high rate of adverse 
effects and intolerance to the combination. Another 
study reported the use of combination of 13 cis-  retinoic 
acid, dexamethasone and IFN-α as maintenance for 
MM patients post ASCT.57 Although responses were 
observed, again many patients discontinued therapy 
due to side effects. The use of bortezomib and lenali-
domide in such combinations might be less toxic and 
warrants investigation. Although preliminary results 
show promising outcomes with lenalidomide mainte-
nance, some patients do not respond as well or may 
not tolerate the drug, and therefore it is important to 
have other options for second line maintenance such 
as IFN-α ± GM-CSF or in other combinations. Indeed 
in this study, we have seen few patients who have 
remained on IFN-α for many years with sustained 
complete  remission.  Perhaps,  sequential  cycling 
maintenance therapy, as reported before,58 might also 
be a better way of overcoming additive toxicity and 
possibly avoiding/delaying the emergence of resistant 
myeloma clones.
In summary, our data confirm that the combina-
tion of GM-CSF with IFN-α is a tolerable and effec-
tive maintenance treatment after ASCT with reduced 
IFN-α induced myelotoxicity and improved PFS in 
patients with multiple myeloma. Our results sup-
port the continued use of IFN-α as a maintenance 
therapy  for  MM  patients  who  have  responded. 
Future  studies  should  investigate  the  addition  of 
newer novel drugs in combination with GM-CSF 
and interferon.
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